HIGHLIGHTS
- who: Pascale Plas and colleagues from the IPSEN Innovation, Les Ulis, France University Hospital Basel, University of Basel, Basel, Switzerland have published the Article: Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours, in the Journal: Pharmaceuticals 2022, 1085 of 27/06/2022
- what: The aim of this present in_vivo/ex vivo study was to compare the anti-tumour activity and the potential toxicity of_[177 Lu]Lu-satoreotide tetraxetan to that of_[177 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.